This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wong, S. J. Articles by Li, Y. Search for Related Content PubMed PubMed Citation Articles by Wong, S. J. Articles by Li, Y.

Locally Recurrent, Previously Irradiated Head and Neck Cancer: Concurrent Re-Irradiation and Chemotherapy, or Chemotherapy Alone?

Stuart J. Wong, Mitchell Machtay, Yi Li

From the Division of Neoplastic Diseases, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI; Department of Radiation Oncology, Jefferson Medical College/ Bodine Cancer Center, Philadelphia, PA; and Harvard School of Public Health, Dana-Farber Cancer Institute, Boston, MA

Address reprint requests to Stuart Wong, MD, Department of Medicine, Division of Neoplastic Diseases, Medical College of Wisconsin, 9200 W Wisconsin Ave, Milwaukee, WI 53226; e-mail: swong{at}mcw.edu

Patients with locally recurrent head and neck cancer previously treated with radiation have a poor prognosis. Administration of a second course of radiation to tissues within a previous radiation portal, has been traditionally considered unsafe. Survival rates of highly selected patients treated with concurrent chemotherapy and re-irradiation may be as high as 25% at 2 years—exceeding the outcome of matched historical controls treated with chemotherapy alone (10%). However, many questions exist regarding the use of re-irradiation. Uncertainty exists over the criteria for selecting patients who are most appropriate for treatment with re-irradiation. Even greater concern exists regarding toxicity and functional sequelae associated with the use of re-irradiation. Whether the benefits of re-irradiation on locoregional disease control and survival outweigh its potentially severe and life-threatening adverse effects is not clear. In this review, we will discuss re-irradiation and other treatment options for squamous cell carcinoma patients with previously irradiated, locoregional recurrent or second primary tumors in the head and neck, and describe a recently initiated randomized trial comparing chemotherapy plus re-irradiation with chemotherapy.

Authors' disclosures of potential con- flicts of interest and author contributions are found at the end of this article.

This article has been cited by other articles:

				N. Choong and E. Vokes Expanding Role of the Medical Oncologist in the Management of Head and Neck Cancer CA Cancer J Clin, January 1, 2008; 58(1): 32 - 53. [Abstract] [Full Text] [PDF]

				A. A. Forastiere, A. Trotti, D. G. Pfister, and J. R. Grandis Head and Neck Cancer: Recent Advances and New Standards of Care J. Clin. Oncol., June 10, 2006; 24(17): 2603 - 2605. [Full Text] [PDF]